Eli Lilly
The latest news about Eli Lilly: headlines, AI summaries and the full story from every source.
- Combining Eli Lilly's Taltz and Zepbound May Improve Psoriasis and Metabolic Benefits
- Eli Lilly Announces Promising Weight Loss Drug Combination
- Eli Lilly and Novo Nordisk Develop Amylin-Based Obesity Drugs as Complement or Alternative to GLP-1s
- Foghorn Therapeutics Downgraded by TD Cowen Following Exit of Partnership with Eli Lilly
- Eli Lilly Expands Weight Loss Drug Access to Low- and Middle-Income Countries
- Eli Lilly's Stock Unaffected by Viking Therapeutics' Strong Clinical Results
- Eli Lilly Halts Development of an Obesity Drug Amid High Standards and Strategic Diversification
- Novo Nordisk outlines growth strategy amid Eli Lilly's expanding GLP-1 lead
- Johnson & Johnson Outperforms Peers Despite Slower Revenue Growth
- Eli Lilly and Novo Nordisk Compete Over Next-Phase Obesity Drug Innovations
- Eli Lilly CEO Highlights Growing Market Share for Foundayo Oral GLP-1 Medication
- Study Finds Weight-Loss Drugs from Novo Nordisk (NVO) and Eli Lilly (LLY) Effective at Lower Doses
- Eli Lilly's Momentum Faces Potential Threat from Competitive GLP-1 Market
- Eli Lilly's Foundayo Gains Rapid Market Share in Oral Weight-Loss Segment
- Eli Lilly Captures Over 30% of New U.S. Patients on Oral Weight-Loss Medications
- Eli Lilly's Supply Constraints and Market Impact
- Billionaires Stanley Druckenmiller and Ken Griffin Increase Stakes in Eli Lilly
- Eli Lilly Reports Positive Clinical Trial Results for Tirzepatide
- Eli Lilly Acquires Merida Biosciences for $2.88 Billion in Autoimmune Disease Expansion
- Eli Lilly's Tirzepatide Shows Strong Results in New Clinical Trials
- Eli Lilly Releases Study Showing Zepbound May Reduce Healthcare Costs
- Eli Lilly Study Shows Zepbound May Reduce Healthcare Costs
- Ken Griffin Increases Stake in Eli Lilly Amid Strong Performance
- Eli Lilly's Stock Surge Was Predictable Based on Publicly Available Information
- GH Research Gains on Potential Acquisition Talks Involving Eli Lilly and Atai Life Sciences
- Oral Wegovy Surpasses Eli Lilly's Zepbound as Top-Selling Weight-Loss Drug
- Eli Lilly's Weight-Loss and Diabetes Drugs Contribute Over Two-Thirds of Q1 Revenue
- Nvidia Invests in Biotech Company Generate, Aligning with CEO's Vision of AI Impact on Life Sciences
- Rising Use of GLP-1 Drugs Benefits Eli Lilly
- Eli Lilly Shares Reach Record High Amid Regulatory and Market Developments
- Eli Lilly Praised for Diabetes Association Conference Results; Novo Nordisk Disagrees
- Eli Lilly Shares Rise on Analyst Upgrade Amid Medicare Obesity Drug Coverage Expansion
- Eli Lilly's Pipeline Shows Early Promising Results in JAK2 Inhibitor Study
- Eli Lilly's Retatrutide Shows Promising Results in Weight Loss Trials
- Eli Lilly's GLP-1 Drugs Face Potential Coverage Reduction by Employers
- Eli Lilly Reports Weight Loss Results Across Menopause Stages in Obesity Drug Trial
- CVS Health Announces Coverage of Eli Lilly's Weight Management Medicines
- Eli Lilly Aims to Leverage GLP-1 Success for Future Acquisitions
- Eli Lilly Regains Coverage with CVS Health in GLP-1 Market
- Eli Lilly's Retatrutide Shows Strong Weight-Loss Results as Next-Gen Therapy
- Eli Lilly CEO's Comments on Foundayo Spark Optimism Among Investors
- Eli Lilly Achieves Coverage of All Obesity Medicines by Major U.S. Pharmacy Benefit Managers
- Eli Lilly CEO Comments on Foundayo Spark Optimism Among Investors
- Wolfe Research Maintains Outperform Rating on Eli Lilly Amid Strong Obesity Drug Data
- Eli Lilly Announces $4 Billion in Acquisitions to Expand Infectious Disease Portfolio
- CVS Health Restores Coverage for Eli Lilly’s Zepbound and Adds Obesity Pill
- Nvidia Becomes Top Company in Russell 1000 Index as Eli Lilly Exits
- Eli Lilly's Retatrutide Shows Strong Phase 3 Results in Obesity Trial
- Analyst Raises Eli Lilly's Price Target Following Strong Q1 Results
- Novo Nordisk and Eli Lilly Compete in Oral Weight Loss Drug Market